

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 September 2009 (24.09.2009)

PCT

(10) International Publication Number
WO 2009/117095 A1

(51) International Patent Classification:

A61K 31/17 (2006.01) C07C 275/18 (2006.01)
A61K 31/27 (2006.01) A61P 43/00 (2006.01)
C07C 271/08 (2006.01)

[CN/US]; 9829 Fieldthorn Street, San Diego, CA 92127 (US).

(21) International Application Number:

PCT/US2009/001688

(22) International Filing Date:

17 March 2009 (17.03.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/069,857	18 March 2008 (18.03.2008)	US
61/123,621	9 April 2008 (09.04.2008)	US
61/207,220	9 February 2009 (09.02.2009)	US
61/209,453	6 March 2009 (06.03.2009)	US

(71) Applicant (for all designated States except US): **ARENA PHARMACEUTICALS, INC.** [US/US]; 6166 Nancy Ridge Drive, San Diego, CA 92121-3223 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TRAN, Thuy-Anh** [US/US]; 4833 Fairport Way, San Diego, CA 92130 (US). **CHEN, Weichao** [US/US]; 10617 Senda Acuario, San Diego, CA 92130 (US). **KRAMER, Bryan, A.** [US/US]; 8863 Duncan Road, San Diego, CA 92131 (US). **SADEQUE, Abu, J.M.** [US/US]; 11828 Pickford Road, San Diego, CA 92131 (US). **SHYFRYNA, Hanna, L.** [BY/US]; 1957 Miro Circle, San Diego, CA 92131 (US). **SHIN, Young-Jun** [KR/US]; 11051 Ice Skate Place, San Diego, CA 92126 (US). **VALLAR, Pureza** [US/US]; 630 Felino Way, Chula Vista, CA 91910 (US). **ZOU, Ning**

(74) Agents: **GODDARD, Christine, A.** et al.; P.O. Box 1022, Minneapolis, MN 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: MODULATORS OF THE PROSTACYCLIN (PGI₂) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

(57) Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI₂ receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

WO 2009/117095 A1